Literature DB >> 7229001

Estradiol and progesterone receptors in human breast fibroadenomas.

F Kuttenn, S Fournier, J C Durand, P Mauvais-Jarvis.   

Abstract

Estradiol and progesterone receptors (ER and PR) were studied in 46 breast fibroadenomas obtained at different periods of the menstrual cycle (n = 38) or from patients under combined estrogen-progestagen contraceptive (n = 4) or substitutive progestagen treatment for progesterone insufficiency (n = 4). Cytosolic and nuclear ER (ERc and ERn) increased throughout the follicular phase and were at their maximal level in the preovulatory phase. They decreased during the luteal phase. PR levels were high in the follicular phase, especially in the cytosol (PRc). PRc then decreased while nuclear progesterone receptor (PRn) increased at the beginning of the luteal phase. Thereafter, PRc and PRn decreased and remained low during the luteal phase. PRc and PRn levels in fibroadenomas from patients under estrogen-progestagen therapy were similar to those found during the luteal phase of untreated patients. In patients receiving a substitutive progestagen treatment to correct progesterone insufficiency, PRn was markedly higher than PRc. The existence of ER and PR in breast fibroadenomas and the variations in their levels during the menstrual cycle or under hormonal treatment provide valuable information on the hormone dependency of breast fibroadenoma.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7229001     DOI: 10.1210/jcem-52-6-1225

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages--immunohistochemical study of 107 cases.

Authors:  J D Jacquemier; J Hassoun; M Torrente; P M Martin
Journal:  Breast Cancer Res Treat       Date:  1990-02       Impact factor: 4.872

Review 2.  Epidemiology and endocrinology of benign breast disease.

Authors:  D Y Wang; I S Fentiman
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

3.  Luteal phase defect and breast cancer genesis.

Authors:  P Mauvais-Jarvis; R Sitruk-Ware; F Kuttenn
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

4.  Effects of danazol on incidence of progesterone and oestrogen receptors in benign breast disease.

Authors:  C Panahy; J R Puddefoot; E Anderson; G P Vinson; C L Berry; M J Turner; C L Brown; A W Goode
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-22

Review 5.  Benign breast diseases.

Authors:  Carine Courtillot; Geneviève Plu-Bureau; Nadine Binart; Corinne Balleyguier; Brigitte Sigal-Zafrani; Vincent Goffin; Frédérique Kuttenn; Paul A Kelly; Philippe Touraine
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-10       Impact factor: 2.673

Review 6.  Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

Review 7.  Antiestrogen action of progesterone in breast tissue.

Authors:  P Mauvais-Jarvis; F Kuttenn; A Gompel
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

8.  Analysis of human mammary fibroadenoma by Ki-67 index in the follicular and luteal phases of menstrual cycle.

Authors:  M F Rego; M A L H Navarrete; G Facina; R Falzoni; R Silva; E C Baracat; A C P Nazario
Journal:  Cell Prolif       Date:  2009-04       Impact factor: 6.831

Review 9.  Fibroadenoma.

Authors:  D M Dent; P J Cant
Journal:  World J Surg       Date:  1989 Nov-Dec       Impact factor: 3.352

10.  Immunohistochemical study of D5 antigen (an oestrogen receptor related protein) in normal breast, benign breast disease, and mammary carcinoma in situ.

Authors:  A Girling; M Caleffi; R J King; R R Millis
Journal:  J Clin Pathol       Date:  1988-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.